ascendis pharma glp-1 receptor agonist weight management diabetes treatments Novo inks deal to develop long-acting GLP-1, other metabolic drugs GLP1 Receptor Agonists—Effects beyond Obesity

18 During a period of rapid weight loss, hepatic cholesterol synthesis and secretion increase, which alters the ratio of cholesterol to bile salts within the gallbladder

This doesnt mean GLP-1s arent valuable products

Additional support was provided by American Diabetes Association Basic Research Awards 7-12-BS-077 (G.G.H) and 1-12-BS-109 (C.A.L.)

The GLP-1RA liraglutide has also been approved for the treatment of obesity at a higher standard dose (3 mg once daily) compared to the standard dose used for T2D treatment (1.2 mg once daily) due to the results of the SCALE study program (37, 38)

Thus, these trials are not thoroughly discussed in this review

Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors